Acclarent Didn't Tell FDA About Adverse Events, Jury Told

Law360, Boston (June 28, 2016, 7:58 PM EDT) -- Medical device maker Acclarent Inc. never told regulators that half the patients in a 2007 study for a sinus clearing device developed infections, even though that information should have been turned over, a federal jury in Boston was told Tuesday.

Dr. Anjum Khan, who helps study medical devices for U.S. Food and Drug Administration clearance, testified that a preliminary study on Acclarent’s Stratus sinus-spacer shortly after it was approved included only information about one patient getting a nosebleed. But as she prepared for testimony in a trial of two former Acclarent executives, she said, she learned that seven of 14 patients...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!